Skip to content
← Full study record

NCT02268253 · MORE INFO

Limitations, agreements, and source contact

Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) · Source last updated 2025-01-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
1. Individual site results may be submitted for publication only after the results of the multicenter study are published, 12 months after study completion at all sites, or notification from Stemline that submission of a multicenter publication is no longer planned. 2. Thereafter, the PI is free to publish the results. 3. The PI is required to furnish Stemline with a copy of any proposed publication or presentation for review and comment at least thirty (30) days prior to submission.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
clinicaltrials@menarinistemline.com
organization
Stemline Therapeutics, Inc.
phone
1-877-332-7967
title
Ira Gupta, MD
Complete source fields
certain Agreement
other Details
1. Individual site results may be submitted for publication only after the results of the multicenter study are published, 12 months after study completion at all sites, or notification from Stemline that submission of a multicenter publication is no longer planned. 2. Thereafter, the PI is free to publish the results. 3. The PI is required to furnish Stemline with a copy of any proposed publication or presentation for review and comment at least thirty (30) days prior to submission.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
clinicaltrials@menarinistemline.com
organization
Stemline Therapeutics, Inc.
phone
1-877-332-7967
title
Ira Gupta, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice